Plasmapheresis in neuroleptic malignant syndrome

被引：4

作者：

Gaitini, L

Fradis, M

Vaida, S

Krimerman, S

Beny, A

机构：

[1] BNAI ZION MED CTR,DEPT OTOLARYNGOL HEAD & NECK SURG,IL-31048 HAIFA,ISRAEL

[2] BNAI ZION MED CTR,INTENS CARE UNIT,IL-31048 HAIFA,ISRAEL

[3] BNAI ZION MED CTR,REG PSYCHIAT SERV,IL-31048 HAIFA,ISRAEL

来源：

ANAESTHESIA | 1997年 / 52卷 / 02期

关键词：

anaesthetics; intravenous; neuroleptics; complications; neuroleptic malignant syndrome;

D O I：

10.1111/j.1365-2044.1997.11-az011.x

中图分类号：

R614 [麻醉学];

学科分类号：

100217 ;

摘要：

Neuroleptic malignant syndrome is a severe and potentially fatal reaction to neuroleptic drugs. Treatment requires withdrawal of the neuroleptic agent, metabolic and cardiovascular support, physical cooling and treatment with dantrolene sodium and bromcriptine mesylate. We report a therapeutic success of plasmapheresis in a case of neuroleptic malignant syndrome in which conventional therapy had failed. We postulate that plasmapheresis may prove to be a useful tool in treating this frequently fatal disease.

引用

页码：165 / 168

页数：4

共 16 条

[1] NEUROLEPTIC MALIGNANT SYNDROME - OCCURRENCE IN A CHILD AFTER RECONSTRUCTIVE SURGERY [J].